Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lihua E

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|November 19, 2025
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II studySwetha Kambhampati Thiruvengadam, Leslie L Popplewell, Alex F Herrera, et al.
Oncoimmunology|March 5, 2016
Comparison of naïve and central memory derived CD8<sup>+</sup> effector cell engraftment fitness and function following adoptive transferXiuli Wang, ChingLam W Wong, Ryan Urak, et al.
Transplantation and Cellular Therapy|May 20, 2026
High incidence of cytomegalovirus infection in patients receiving standard of care CD19- or BCMA-targeted CAR T-cell therapies for hematologic malignanciesTamer Othman, John H Baird, Yan Wang, et al.
Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.
Plos One|December 21, 2013
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaLihua E Budde, Carolina Berger, Yukang Lin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 28, 2017
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture ConditionsSang Yun Lee, Philip Olsen, Dong Hoon Lee, et al.
Cancers|March 29, 2023
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell LymphomaColton Ladbury, Savita Dandapani, Claire Hao, et al.
Future Oncology (London, England)|June 22, 2021
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignanciesNina Shah, Miguel-Angel Perales, Cameron J Turtle, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory ProgramSylvia O Dulan, Kathie L Viers, Jamie R Wagner, et al.
Cancer Immunology Research|May 20, 2016
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of RituximabGregory A Rufener, Oliver W Press, Philip Olsen, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|November 19, 2025
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II studySwetha Kambhampati Thiruvengadam, Leslie L Popplewell, Alex F Herrera, et al.
Oncoimmunology|March 5, 2016
Comparison of naïve and central memory derived CD8<sup>+</sup> effector cell engraftment fitness and function following adoptive transferXiuli Wang, ChingLam W Wong, Ryan Urak, et al.
Transplantation and Cellular Therapy|May 20, 2026
High incidence of cytomegalovirus infection in patients receiving standard of care CD19- or BCMA-targeted CAR T-cell therapies for hematologic malignanciesTamer Othman, John H Baird, Yan Wang, et al.
Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.
Plos One|December 21, 2013
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaLihua E Budde, Carolina Berger, Yukang Lin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 28, 2017
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture ConditionsSang Yun Lee, Philip Olsen, Dong Hoon Lee, et al.
Cancers|March 29, 2023
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell LymphomaColton Ladbury, Savita Dandapani, Claire Hao, et al.
Future Oncology (London, England)|June 22, 2021
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignanciesNina Shah, Miguel-Angel Perales, Cameron J Turtle, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory ProgramSylvia O Dulan, Kathie L Viers, Jamie R Wagner, et al.
Cancer Immunology Research|May 20, 2016
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of RituximabGregory A Rufener, Oliver W Press, Philip Olsen, et al.
Pageof 8